Both RT+anlotinib and RT+anti-PD-L1+anlotinib could significantly increase the CD4+ T cells comparing with control (CD4+ T cells: 37.6% ± 5.9% vs. 17.7% ± 0.2%, p = 0.01; 31.9% ± 2.1% vs. 17.7% ± 0.2%, p = 0.0005), whereas RT, anti-PD-L1, and RT+anti-PD-L1 decreased the CD4+ T cells in tumor microenvironment. Here, CD4 is linked to neoplasm.